Kevin T Webster

US Patent:

6407124, Jun 18, 2002

Filed:

Jun 10, 1999

Appl. No.:

09/329616

Inventors:

David B. Rawlins - Morrisville PA
S. David Kimball - E. Windsor NJ
Kyoung S. Kim - North Brunswick NJ
Raj N. Misra - Hopewell NJ
Kevin R. Webster - Yardley PA

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 314439

US Classification:

514342, 514371, 5462707, 548195

Abstract:

Compounds of the formula and pharmaceutically acceptable salts thereof are provided.

US Patent:

6521759, Feb 18, 2003

Filed:

Apr 20, 2001

Appl. No.:

09/839751

Inventors:

Kyoung S. Kim - North Brunswick NJ
S. David Kimball - East Windsor NJ
David B. Rawlins - Morrisville PA
Raj N. Misra - Hopewell NJ
Michael A. Poss - Lawrenceville NJ
Kevin R. Webster - Yardley PA
John T. Hunt - Princeton NJ
Wen-Ching Han - Newtown PA

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07D41712

US Classification:

548184

Abstract:

The present invention describes compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R , R , R , R , R , m and n are as defined in the specification. The compounds of formula I are protein kinase inhibitors and are useful in the treatment of proliferative diseases, for example, cancer, inflammation and arthritis. They may also be useful in the treatment of Alzheimers disease, chemotherapy-induced alopecia, and cardiovascular disease.

US Patent:

6534531, Mar 18, 2003

Filed:

Apr 26, 2001

Appl. No.:

09/842595

Inventors:

S. David Kimball - East Windsor NJ
Kevin R. Webster - Yardley PA
David K. Bol - Langhorne PA

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31425

US Classification:

514369, 514370, 514371

Abstract:

The invention provides a method for preventing or treating alopecia induced by chemotherapy or radiotherapy by administering to a mammalian specie in need thereof a therapeutically effective amount of a compound of formula I or II or a pharmaceutically acceptable salt thereof.

US Patent:

6720347, Apr 13, 2004

Filed:

Mar 29, 2002

Appl. No.:

10/112133

Inventors:

David B. Rawlins - Morrisville PA
S. David Kimball - E. Windsor NJ
Kyoung S. Kim - North Brunswick NJ
Raj N. Misra - Hopewell NJ
Kevin R. Webster - Yardley PA

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31426

US Classification:

514371, 5462707, 548195, 514342

Abstract:

Compounds of the formula and pharmaceutically acceptable salts thereof, wherein R and A are defined herein, are protein kinase inhibitors and are useful in the treatment of proliferative diseases, for example, cancer, inflammation and arthritis. They may also be useful in the treatment of Alzheimers disease and cardiovascular disease.

US Patent:

20070105114, May 10, 2007

Filed:

Jul 29, 2004

Appl. No.:

10/567867

Inventors:

Martha Li - Short Hills NJ, US
Brent Rupnow - Ewing NJ, US
Kevin Webster - Hopkinton MA, US
Donald Jackson - Lawrenceville NJ, US
Tai Wong - Belle Mead NJ, US

International Classification:

C12Q 1/68
G01N 33/574

US Classification:

435006000, 435007230

Abstract:

Biomarkers having expression patterns that correlate with a response of cells to treatment with one or more cdk modulating agents, and uses thereof. Also provided are methods for testing or predicting whether a mammal will respond therapeutically to a method of treating cancer that comprises administering an agent that modulates cdk activity.

US Patent:

60403217, Mar 21, 2000

Filed:

Oct 21, 1998

Appl. No.:

9/176239

Inventors:

Kyoung S. Kim - North Brunswick NJ
S. David Kimball - East Windsor NJ
David B. Rawlins - Morrisville PA
Raj N. Misra - Hopewell NJ
Michael A. Poss - Lawrenceville NJ
Kevin R. Webster - Yardley PA
John T. Hunt - Princeton NJ
Wen-Ching Han - Newtown PA

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31425
C07D41712

US Classification:

514369

Abstract:

Compounds of the formula ##STR1## and pharmaceuticaly acceptable salts thereof. As used in formula I, and throughout the specification, the symbols have the following meanings: R. sub. 1 and R. sub. 2 are independently hydrogen, fluorine or alkyl; R. sub. 3 is aryl or heteroaryl R. sub. 4 is hydrogen, alkyl, cycloalkyl, aryl, cycloalkylalkyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl; or CO-alkyl, CONH-alkyl, COO-alkyl, SO. sub. 2 -alkyl, C(NCN)NH-alkyl, C(NNO. sub. 2)NH-alkyl, C(NH)NH-alkyl, C(NH)NHCO-alkyl, C(NOR. sub. 6)NH-alkyl, R. sub. 5 is hydrogen or alkyl; R. sub. 6 is hydrogen, alkyl, cycloalkyl, aryl, cycloalkylakyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl; m is an integer of 0 to 2; and n is an integer of 1 to 3. The compounds of formula I are protein kinase inhibitors and are useful in the treatment and prevention of proliferative diseases, for example, cancer, inflammation and arthritis.

US Patent:

61073059, Aug 22, 2000

Filed:

Dec 11, 1998

Appl. No.:

9/209575

Inventors:

Raj N. Misra - Hopewell NJ
S. David Kimball - East Windsor NJ
David B. Rawlins - Morrisville PA
Kevin R. Webster - Yardley PA
Isia Bursuker - Cheshire CT

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31435
C07D47104

US Classification:

514303

Abstract:

Compounds of the formula ##STR1## and pharmaceutically acceptable salts thereof for use as inhibitors of cyclin dependent kinases, wherein: X is O, S(O). sub. m ; Y is alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl; R. sub. 1 is hydrogen or lower alkyl; R. sub. 2 is alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, --O-alkyl, --O-aryl, --NR. sub. 4 R. sub. 5 ; R. sub. 3 is hydrogen or lower alkyl; R. sub. 4 is hydrogen, alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, --O-alkyl, --O-aryl; R. sub. 5 is hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, alkylheterocycloalkyl, --O-alkyl, --O-aryl; and m is 0, 1 or 2. The compounds of formula I are protein kinase inhibitors and are useful in the treatment and prevention of proliferative diseases, for example, cancer, inflammation and arthritis.

US Patent:

62620967, Jul 17, 2001

Filed:

Dec 15, 1999

Appl. No.:

9/464511

Inventors:

Kyoung S. Kim - North Brunswick NJ
S. David Kimball - East Windsor NJ
David B. Rawlins - Morrisville PA
Raj N. Misra - Hopewell NJ
Michael A. Poss - Lawrenceville NJ
Kevin R. Webster - Yardley PA
John T. Hunt - Princeton NJ
Wen-Ching Han - Newtown PA

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 31425

US Classification:

514369

Abstract:

Compounds of the formula ##STR1## and pharmaceutically acceptable salts thereof. R. sub. 1 and R. sub. 2 are independently hydrogen, fluorine or alkyl; R. sub. 3 is aryl or heteroaryl R. sub. 4 is alkyl, cycloalkyl, aryl, cycloalkylalkyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl; m is an integer of 0 to 2; and n is an integer of 1 to 3. The compounds of formula I are protein kinase inhibitors and are useful in the treatment and prevention of proliferative diseases, for example, cancer, inflammation and arthritis. They may also be useful in the treatment of neurodegenerative diseases such as Alzheimer's disease, cardiovascular diseases, viral diseases and fungal diseases.